Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

A Predictive Score for Early Mortality during Induction Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma - an Analysis from Five GMMG and HOVON Multicenter Phase III Trials

Blood (2017) 130 (Supplement 1): 2016.

https://doi.org/10.1182/blood.V130.Suppl_1.2016.2016

Published: 2017

Journal Articles

Centrosomal Clustering – a Novel Therapeutic Target for Multiple Myeloma.

Marc S Raab, MD, Iris Breitkreutz, MD, Blanka Rebacz, PhD, Thomas O Larsen, PhD, Ludmila Wagner, MSc, Patrick Hayden, MD, MRCPath, Anthony D. Ho, MD, PhD, Mads H Clausen, PhD, Hartmut Goldschmidt, MD, Kenneth C. Anderson, MD, Alwin Kraemer, MD

Blood (2009) 114 (22): 300.

https://doi.org/10.1182/blood.V114.22.300.300

Published: 2009

Journal Articles

Targeting Proteinkinase C Alters ER-Stress and b-Catenin Signaling in Multiple Myeloma: Therapeutic Implications.

Marc S. Raab, MD, Klaus Podar, MD, PhD, Jing Zhang, MSc, Giovanni Tonon, MD, Johannes H. Fruehauf, MD, Iris Breitkreutz, MD, Boris K. Lin, MD, PhD, Teru Hideshima, MD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2007) 110 (11): 258.

https://doi.org/10.1182/blood.V110.11.258.258

Published: 2007

Journal Articles

Targeting CCR1 for the Treatment of Osteolytic Bone Disease in Multiple Myeloma.

Sonia Vallet, MD, Noopur Raje, MD, MariaTeresa Fulciniti, Kenji Ishitsuka, MD, Teru Hideshima, MD, Klaus Podar, MD, Samantha Pozzi, MD, Iris Breitkreutz, MD, Tanyel Kiziltepe, PhD, Yutaka Okawa, MD, Hiroshi Ikeda, MD, Loredana Santo, MD, Siddhartha Mukherjee, MD, Nileshwari Vaghela, Diana Cirstea, MD, Mario Boccadoro, MD, Kenneth C. Anderson, MD

Blood (2007) 110 (11): 2503.

https://doi.org/10.1182/blood.V110.11.2503.2503

Published: 2007

Journal Articles

The Novel, Orally Available Multi-Kinase Inhibitor BAY 73-4506 Targets Myeloma Cells and Their Bone Marrow Microenvironment.

Marc S. Raab, MD, Iris Breitkreutz, MD, Podar Klaus, MD, PhD, Jing Zhang, MSc, Simona Blotta, MD, Olaf Christensen, MD, Teru Hideshima, MD, Dharminder Chauhan, PhD, Scott Wilhelm, PhD, Kenneth C. Anderson, MD

Blood (2007) 110 (11): 2525.

https://doi.org/10.1182/blood.V110.11.2525.2525

Published: 2007

Journal Articles

Multiple Myeloma Cell-Osteoblast Interaction Results in Impaired Bone Formation.

Sonia Vallet, MD, Teru Hideshima, MD, Samantha Pozzi, MD, Nileshwari Vaghela, Gaurav Gharti-Chhetri, Siddhartha Mukherjee, MD, Iris Breitkreutz, MD, Tanyel Kiziltepe, PhD, Yutaka Okawa, MD, Hiroshi Ikeda, MD, Loredana Santo, MD, Diana Cirstea, MD, Mario Boccadoro, MD, Kenneth C. Anderson, MD, Noopur Raje, MD

Blood (2007) 110 (11): 4764.

https://doi.org/10.1182/blood.V110.11.4764.4764

Published: 2007

Journal Articles

Lenalidomide and Bortezomib: Targeting Osteoclastogenesis, Osteoclast Survival Factors, and Bone Remodeling Markers in Multiple Myeloma.

Iris Breitkreutz, MD, Marc S. Raab, MD, Sonia Vallet, MD, Teru Hideshima, MD, Noopur Raje, MD, Constantine Mitsiades, MD, PhD, Dharminder Chauhan, PhD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2007) 110 (11): 1184.

https://doi.org/10.1182/blood.V110.11.1184.1184

Published: 2007

Journal Articles

Targeting PKC in Multiple Myeloma: In Vitro and In Vivo Effects of the Novel, Orally Available Small-Molecule Inhibitor Enzastaurin (LY317615.HCl).

Marc S. Raab, MD, Klaus Podar, MD, PhD, Jing Zhang, MSc, Douglas McMillin, PhD, Iris Breitkreutz, MD, Yu-Tzu Tai, PhD, Boris Lin, MD, PhD, Irene Ghobrial, MD, Nikhil Munshi, MD, Teru Hideshima, MD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2006) 108 (11): 3466.

https://doi.org/10.1182/blood.V108.11.3466.3466

Published: 2006

Journal Articles

AZD6244 (ARRY-142886), a Potent and Selective MEK1/2 Inhibitor Blocks the ERK1/2 Signaling Pathway, Inhibits Osteoclast Differentiation and Activation in Multiple Myeloma: Clinical Implications.

Iris Breitkreutz, MD, Sonia Vallet, MD, Marc S. Raab, MD, Xianfeng Li, Noopur Raje, MD, Teru Hideshima, MD, PhD, Dharminder Chauhan, PhD, Nikhil Munshi, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2006) 108 (11): 3467.

https://doi.org/10.1182/blood.V108.11.3467.3467

Published: 2006

Journal Articles

Lenalidomide and Bortezomib Inhibit Osteoclast Differentiation and Activation in Multiple Myeloma: Clinical Implications.

Iris Breitkreutz, MD, Sonia Vallet, MD, Marc S. Raab, MD, Yu-Tzu Tai, PhD, Noopur Raje, MD, Teru Hideshima, MD,PhD, Dharminder Chauhan, PhD, Nikhil C. Munshi, MD, Paul Richardson, MD, Kenneth C. Anderson, MD

Blood (2006) 108 (11): 3485.

https://doi.org/10.1182/blood.V108.11.3485.3485

Published: 2006

Journal Articles

MLN3897, a Novel CCR1 Antagonist, Inhibits Osteoclastogenesis by Blocking Early ERK Activation.

Sonia Vallet, MD, Noopur Raje, MD, Kenji Ishitsuka, MD, Teru Hideshima, MD, Klaus Podar, MD, Petter Veiby, Iris Breitkreutz, MD, Tanyel Kizeltepe, PHD, Hiroshi Yasui, MD, Enrique M. Ocio, MD, Norihiko Shiraishi, Marco Ladetto, MD, Mario Boccadoro, MD, Kenneth C. Anderson, MD

Blood (2006) 108 (11): 1636.

https://doi.org/10.1182/blood.V108.11.1636.1636

Published: 2006

Journal Articles

CD27-Mediated Apoptosis Is Dependent on Siva-Induced Caspase Activation in Human Multiple Myeloma.

Yu-Tzu Tai, PhD, Xian-Feng Li, MS, Rory Coffey, BS, Iris Breitkreutz, MD, Laurence Catley, MBBS FRACP FRCPA, Robert L. Schlossman, MD, Paul G. Richardson, MD, Nikhil C. Munshi, MD, Steven P. Treon, MD, PhD, Kenneth C. Anderson, MD

Blood (2005) 106 (11): 3398.

https://doi.org/10.1182/blood.V106.11.3398.3398

Published: 2005

Journal Articles

Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40-Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications.

Yu-Tzu Tai, PhD, Laurence Catley, MD, Xian-Feng Li, MS, Rory Coffey, BS, Iris Breitkreutz, MD, Jooeun Bae, PhD, Klaus Podar, MD, PhD, Teru Hideshima, MD, PhD, Dharminder Chauhan, PhD, Robert Schlossman, MD, Paul Richardson, MD, Steven P. Treon, MD, PhD, Iqbal S. Grewal2, PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD

Blood (2005) 106 (11): 5150.

https://doi.org/10.1182/blood.V106.11.5150.5150

Published: 2005

Journal Articles

Role of BAFF in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment.

Yu-Tzu Tai, PhD, Xian-Feng Li, MS, Rory Coffey, BS, Iris Breitkreutz, MD, Laurence Catley Laurence Catley, MBBS, FRACP, FRCPA, Klaus Podar, MD, PhD, Teru Hideshima, MD, PhD, Dharminder Chauhan, PhD, Noopur Raje, MD, Robert Schlossman, MD, Paul Richardson, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD

Blood (2005) 106 (11): 627.

https://doi.org/10.1182/blood.V106.11.627.627

Published: 2005

Journal Articles

Chromosomal Deletions and Amplifications in Multiple Myeloma Detected by 500K Single Nucleotide Polymorphism Array Analysis.

Yu-Tzu Tai, PhD, Cheng Li, PhD, Rory Coffey, BS, Iris Breitkreutz, MD, Xian-Feng Li, MS, Laurence Laurence Catley, MBBS FRACP FRCPA, Robert L. Schlossman, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2005) 106 (11): 1551.

https://doi.org/10.1182/blood.V106.11.1551.1551

Published: 2005

Journal Articles

No Influence of Previous Thalidomide Administration on Peripheral Blood Stem Cell Collection in Patients with Multiple Myeloma.

Iris Breitkreutz, MD, Axel Benner, Friedrich W. Cremer, MD, Doris Herrmann, Anthony D. Ho, MD, PhD, Hartmut Goldschmidt, MD

Blood (2004) 104 (11): 4902.

https://doi.org/10.1182/blood.V104.11.4902.4902

Published: 2004

NARROW

A Predictive Score for Early Mortality during Induction Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma - an Analysis from Five GMMG and HOVON Multicenter Phase III Trials

Centrosomal Clustering – a Novel Therapeutic Target for Multiple Myeloma.

Targeting Proteinkinase C Alters ER-Stress and b-Catenin Signaling in Multiple Myeloma: Therapeutic Implications.

Targeting CCR1 for the Treatment of Osteolytic Bone Disease in Multiple Myeloma.

The Novel, Orally Available Multi-Kinase Inhibitor BAY 73-4506 Targets Myeloma Cells and Their Bone Marrow Microenvironment.

Multiple Myeloma Cell-Osteoblast Interaction Results in Impaired Bone Formation.

Lenalidomide and Bortezomib: Targeting Osteoclastogenesis, Osteoclast Survival Factors, and Bone Remodeling Markers in Multiple Myeloma.

Targeting PKC in Multiple Myeloma: In Vitro and In Vivo Effects of the Novel, Orally Available Small-Molecule Inhibitor Enzastaurin (LY317615.HCl).

AZD6244 (ARRY-142886), a Potent and Selective MEK1/2 Inhibitor Blocks the ERK1/2 Signaling Pathway, Inhibits Osteoclast Differentiation and Activation in Multiple Myeloma: Clinical Implications.

Lenalidomide and Bortezomib Inhibit Osteoclast Differentiation and Activation in Multiple Myeloma: Clinical Implications.

MLN3897, a Novel CCR1 Antagonist, Inhibits Osteoclastogenesis by Blocking Early ERK Activation.

CD27-Mediated Apoptosis Is Dependent on Siva-Induced Caspase Activation in Human Multiple Myeloma.

Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40-Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications.

Role of BAFF in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment.

Chromosomal Deletions and Amplifications in Multiple Myeloma Detected by 500K Single Nucleotide Polymorphism Array Analysis.

No Influence of Previous Thalidomide Administration on Peripheral Blood Stem Cell Collection in Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only